Brain/Neuro Cancer: Newly Diagnosed Clinical Trials

Showing 1-10 of 10 items
1.
2.
  • Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma
  • RATIONALE: Giving chemotherapy before an autologous stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy or radiation therapy is given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. PURPOSE: This randomized phase II trial studies how well combination chemotherapy given together with autologous stem cell transplant works compared to combination chemotherapy alone in treating patients with central nervous system B-cell lymphoma.
  • Diagnoses: Brain/Neuro Cancer: Newly Diagnosed
  • Status: Recruiting
3.
  • Phase 2 Study of MEDI4736 in Patients With Glioblastoma
  • This is an open-label, non-randomized, multicenter Phase 2 study of MEDI4736 with three non-comparative cohorts: Cohort A: 37 Patients with newly diagnosed unmethylated MGMT GBM will receive MEDI4736 every 2 weeks in combination with standard radiotherapy. Cohort B: 30 bevacizumab-naïve patients with recurrent GBM will receive MEDI4736 every 2 weeks as monotherapy. Cohort C: 17 bevacizumab-refractory patients with recurrent GBM will receive MEDI4736 every 2 weeks in combination with continued bevacizumab.
  • Diagnoses: Brain/Neuro Cancer: Newly Diagnosed
  • Status: Recruiting
4.
5.
6.
  • Ph I Personalized NeoAntigen Cancer Vaccine With Radiotherapy for Patients With MGMT Unmethylated, Newly Diagnosed Glioblastoma
  • This research study is studying a new type of vaccine as a possible treatment for patients with MGMT-unmethylated glioblastoma. This research study is a Phase I clinical trial, which tests the safety of an investigational intervention and also tries to define the appropriate dose of the intervention to use for further studies. "Investigational" means that the intervention is being studied and that research doctors are trying to find more about it. It also means that the FDA (U.S. Food and Drug Administration) has not approved the Personalized NeoAntigen Cancer Vaccine for any use in patients, including people with glioblastoma. The purpose of this study is to determine if it is possible to make and administer safely a vaccine against glioblastoma by using information gained from specific characteristics of the participants tumor. It is known that glioblastomas have mutations (changes in genetic material) that are specific to an individual patient's tumor. These mutations can cause the tumor cells to produce proteins that appear very different from the body's own cells. It is possible that these proteins used in a vaccine may induce strong immune responses, which may help the body fight any tumor cells that could cause the glioblastoma to come back in the future.
  • Diagnoses: Brain/Neuro Cancer: Newly Diagnosed
  • Status: Recruiting
7.
8.
9.
10.
Showing 1-10 of 10 items
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms